Interview with Daniel Ghozzi, Managing Director UCB CIS, UCB Russia/CIS
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
Address: Shabolovka str. 10 Building 2, floor 3 RUS – 119048 Moscow,Russia
Tel: +7 495 644 3322
Web: http://www.ucb.com/
UCB, headquartered in Brussels, Belgium, is a global biopharma company with a team of over 8500 talented employees, a strong market presence in more than 40 countries, € 3.2 billion in revenue (2010) and numerous strategic partnerships across the industry.
UCB operates in Russia and 11 CIS countries. It’s main office is in Moscow, Russia.
UCB’s medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field
Epilepsy
Parkinson’s disease
Restless Legs Syndrome
Crohn’s disease
Rheumatoid arthritis
Allergies
Respiratory disease
Regulating cerebral functions
Attention Deficit Hyperactivity Disorder (ADHD)
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
Valenta was established in 1997 as Otechestvennye Lekarstva, and today represents the consolidation of several facilities and business holding groups. Can you give our readers an overview of the company’s…
Since 2006, Russia has witnessed quite a dynamic few years, with sweeping legislative reforms like the Law on Circulation of Medicines and development strategies like Pharma 2020. What have been…
Baker & McKenzie differentiates itself from competitors by offering an industry-focused practice. Has this model continued to give this company a leading edge in Russia, and, overall, what is your…
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Ferring is a specialty biopharmaceutical company that operates in four strategic therapeutic areas. Globally, many pharma companies have been diversifying their portfolio, and entering the OTC segment, generics segment, medical…
Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in Russia? The size of…
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
The AEB works through a number of channels to promote the interests of European corporations with operations in Russia. It has a long history in this country, dating back to…
Novo Nordisk announced last year the development of an insulin plant in the Kaluga region not far from Moscow. What is the strategic significance of this plant, both for the…
Many expat managers have used Russia as a stepping-stone, but you have headed this business for an astounding 9 years. What is it about this country and about Reckitt Benckiser’s…
See our Cookie Privacy Policy Here
